Temozolomide plus atezolizumab for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies temozolomide plus atezolizumab in people with metastatic or recurring small cell lung cancer that has already come back or progressed after standard platinum chemotherapy plus immunotherapy. It may help by trying a new combination after prior treatment has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older, and be able to sign consent and allow your medical information to be shared for the study
- Have “ECOG” health/ability score of 0 to 2 (a clinician-rated measure of how well you function day to day)
- Have extensive-stage small cell lung cancer that has progressed or returned after platinum chemotherapy with immunotherapy, and have measurable tumors on scans
- Have had no more than 3 prior cancer treatment “lines” for metastatic disease, and you must not have had temozolomide before
- Have blood counts and organ function in safe ranges (for example, neutrophils, platelets, kidney function, liver tests, and albumin)
- Be able to take pills by mouth and swallow/keep oral medicine, and be expected to live more than 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiation therapy to standard immune therapy (atezolizumab) after initial chemo can help people with extensive-stage small cell lung cancer live longer and control the cancer better. You must have a good response (partial response) or stable disease after initial treatment, plus several lab/imaging checks to confirm safety.
This trial tests adding a new drug, iadademstat, to standard immunotherapy drugs (atezolizumab or durvalumab) for people with small cell lung cancer that responded to initial treatment. The goal is to see if this combination works better at preventing cancer from returning.
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
This trial looks at adding atezolizumab to chemotherapy before surgery for resectable, non-squamous non-small cell lung cancer. It also tries to predict which patients will respond best using your tumor tissue.
This trial studies a two-drug treatment (cabozantinib plus atezolizumab) for people with advanced or metastatic non-small cell lung cancer (NSCLC). It may help control the cancer and shrink tumors, especially for patients whose tumor tests show low PD-L1 and who fit the trial’s prior-treatment rules.
Hear when a new Extensive Stage Lung Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.